Hello Researchondemand,
Thank you for your question.
I've organized a digest of links to statistics related to what you
listed in your question.
In 2001, the total U.S. anti-migraine market was approximately $1.7
billion and grew at an average annual growth rate of 16% from 1997 to
2001. According to the National Headache Foundation, there are 28
million people in the United States who suffer from migraine headaches
http://www.finanznachrichten.de/nachrichten/artikel-1116612.asp
According to the Data Monitor,Migraines: sales of triptans to double
by 2007
“Triptans, developed to reduce side effects and lack of efficacy
associated with ergotamines and DHE, have become successful
anti-migraine drugs. The market is now worth $1.7 billion and will
double over the next seven years, to reach $3.5 billion in 2007.
Meanwhile, growth in the ergotamine class will slow and eventually
decline as triptans and other alternatives receive greater attention.”
http://www.datamonitor.com/~808430005cd945d98fcaeffe3b0af63c~/healthcare/news/product.asp?pid=0F6D380C-E764-4306-91A2-1AD0828EBBA4
According to OSF Healthcare there are 28 million people in the U.S.
suffering from migraine headaches and 75% of the sufferers are women.
http://www.stayinginshape.com/3osfcorp/libv/i06.shtml
28 million Americans suffer from migraines
“CHICAGO, IL -- January 18, 2002 - The impact of migraines on society,
and the U.S. economy, is quite significant. In fact, the 28 million
American migraine sufferers equate to nearly 13 percent of the
population, and cost the nation's economy approximately $13 billion a
year. According to the recently updated American Migraine Study, this
disabling biological disease affects work and school productivity in
more than half of the patients, and household productivity in nearly
two-thirds of patients.”
National Headache Foundation Website
http://www.headaches.org/professional/press%20releases/release011802.html
The American Migraine Study II, a ten-year report card which measures
the prevalence of migraine headache in the U.S. was released at the
13th Annual Conference of the Diamond Headache Clinic Research and
Education Foundation, held in Palm Springs, CA, on February 22, 2000.
“An astonishing 28 million Americans are migraine sufferers; migraine
headaches affect one out of every four households in the United
States. This is 13% of the population. Untreated migraine headaches
cause a significant reduction in the quality of life for sufferers.
Migraines account for a tremendous loss of time from work, school, and
household activities for many patients. Fifty-one percent of sufferers
report that during an attack they experience a 50% or more reduction
in work and/or school productivity; 66% report a 50% or more reduction
in household work. Thirty-nine percent of sufferers report pain so
severe that they are driven to their beds--sometimes for days at a
time.”
http://womenshealth.about.com/library/weekly/aa022400a.htm
Market share for "triptan" medications:
Imitrex 70% of U.S. Market
Page 12 of this publication by RBC Capital Market Research
https://www.rbccmresearch.com/drw1.0.4/pdf/0,,28827,00.pdf
Zomig 16.2% of U.S. Market
Page 1 of this publication by RBC Capital Market Research
https://www.rbccmresearch.com/drw1.0.4/pdf/0,,33174,00.pdf
On page 14 of the publication by Provider Synergies there is chart
showing the market share of Triptans:
Imitrex (sumatriptan) 60%
Maxalt (rizatriptan) 16%
Zomig (zolmitriptan) 18%
Amerge (naratriptan) 5%
http://www.dhh.state.la.us/MEDICAID/P&TCommittee/Minutes/LAM%20030602MJ.pdf
Additional information that may interest you:
TOP 200 BRAND-NAME DRUGS BY RETAIL SALES IN 2001
http://dt.pdr.net/be_core/d/templates/issue/show_article.jsp?stylesheet=/be_core/d/stylesheets/xslt/view_free_pages.xsl&filename=/be_core/d/online_only_content/free_pages/brand2001.xml&showPoll=no
TOP 200 GENERIC DRUGS BY RETAIL SALES IN 2001
http://dt.pdr.net/be_core/d/templates/issue/show_article.jsp?stylesheet=/be_core/d/stylesheets/xslt/view_free_pages.xsl&filename=/be_core/d/online_only_content/free_pages/generic2001.xml&showPoll=no
A recent article dated July 5, 2002 “Migraine: triptans jostle for
position in an overcrowded crowded market.”
http://www.datamonitor.com/~808430005cd945d98fcaeffe3b0af63c~/healthcare/News/product.asp?pid=6AC78959-9745-4D42-AA54-1BC139BD3873
Search Criteria:
U.S. Triptan market
U.S. migraine market
U.S. migraine market size
Imitrex market share
Maxalt market share
Zomig market share
Amerge market share
U.S. migraine sufferers
migraine medication sales +U.S.
I hope this information meets your needs.
Best Regards,
Bobbie7-ga |
,
0 Comments
)